Next Phase Newsletter

Established in 2017, a venture capital fund is a new addition to its sister fund, a $60M+ venture capital partnership. The firm is focused on companies that contribute to the delivery of “Delightful Moments”, in other words technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. The firm has offices in USA and Western Europe, and expanded into Western Europe in early 2019. Currently, the firm is focused on investing in companies based in the USA and Western Europe.

The firm is interested in companies dedicated to the “technological vectors of happiness”. Such technologies include genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. Initially, the firm did not invest in traditional biopharmaceuticals or medical devices, but the firm has expanded their interests and now actively seeking opportunities in therapeutics and devices with a focus on early-stage, pre-IND companies.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A corporate venture arm of a large company specializing in infection prevention technology is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products into the market. Within the area of infection prevention and control, the firm will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm Investments will invest globally.

The firm has a focus on digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection.

The firm will only make strategic investments that align with the company’s vision. The firm is an active investor, and will typically take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly founded venture capital firm headquartered in Europe with an additional office based in the USA is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stay away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic venture capital arm and innovation group of a large health system manages both a seed fund as well as a later-stage corporate venture fund, both dedicated to medtech and healthcare IT. In addition, the group also has an incubator and innovation group that looks to develop and integrate IP generated internally and externally that can be leveraged by the health system. Seed investments usually range from $100k – $500k with additional capital reserved for follow on investments, typically allocating up to $1.5M over the life of the investment. Later stage investments are usually in the range of $1M-$2M. The group is flexible in terms of structure but typically refers convertible notes for seed deals and straight equity for later-stage investments. The firm may lead investments or invest with a syndicate and looks to be active in portfolio companies’ development and add value at the board level as well as through integration into the health system.

The firm is exclusively focused on the medtech and digital health/healthcare IT sectors. The group is fairly opportunistic in these areas, but looks for technologies that can be leveraged by the health system. Both pre-revenue and pre-FDA approval devices, as well as commercial/revenue-generating companies, will be considered. The firm has no preference for regulatory pathway and has a particular interest in the cardio space.

The firm has historically focused on startups in the midwestern United States, however, is looking more broadly and open to companies across the U.S. The group favors strong management teams that are open to working closely together.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A small, socially responsible VC firm focused specifically on ophthalmic investments invests in drugs, devices, and diagnostics that improve and preserve vision. The firm looks to identify and bring forward early stage investments with our deep knowledge of the space. The firm is currently allocating $100,000-$750,000 utilizing convertible notes in seed stage companies and equity in post seed stage companies. The firm is interested in co-investing as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe.

The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions.  The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low- and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest.  The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital.

The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field.  The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada was founded by a healthcare investment team that has a successful track record of identifying, building, and growing life science companies. The firm recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later-stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with like-minded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

With offices worldwide, a large medtech company invests in medical technology companies that are strategically relevant. The firm invests in new technologies via venture investing, collaborations, incubation, or M&A. The firm invests worldwide.

The firm’s primary focuses within healthcare include in-vitro diagnostics (particularly immuno and molecular diagnostics), digital lab services (including capacity management, care coordination, technologies that help physicians make diagnoses and other key decisions) and AI technologies in healthcare. The firm will invest in any medical indication area, and prefers companies that have at least attained proof of concept data or with a product on market demonstrating traction and revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.